Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure
Top Cited Papers
Open Access
- 31 October 2002
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (18) , 1403-1411
- https://doi.org/10.1056/nejmoa021266
Abstract
The Digitalis Investigation Group trial reported that treatment with digoxin did not decrease overall mortality among patients with heart failure and depressed left ventricular systolic function, although it did reduce hospitalizations slightly. Even though the epidemiologic features, causes, and prognosis of heart failure vary between men and women, sex-based differences in the effect of digoxin were not evaluated. We conducted a post hoc subgroup analysis to assess whether there were sex-based differences in the effect of digoxin therapy among the 6800 patients in the Digitalis Investigation Group study. The presence of an interaction between sex and digoxin therapy with respect to the primary end point of death from any cause was evaluated with the use of Mantel–Haenszel tests of heterogeneity and a multivariable Cox proportional-hazards model, adjusted for demographic and clinical variables. There was an absolute difference of 5.8 percent (95 percent confidence interval, 0.5 to 11.1) between men and women in the effect of digoxin on the rate of death from any cause (P=0.034 for the interaction). Specifically, women who were randomly assigned to digoxin had a higher rate of death than women who were randomly assigned to placebo (33.1 percent vs. 28.9 percent; absolute difference, 4.2 percent, 95 percent confidence interval, –0.5 to 8.8). In contrast, the rate of death was similar among men randomly assigned to digoxin and men randomly assigned to placebo (35.2 percent vs. 36.9 percent; absolute difference, –1.6 percent; 95 percent confidence interval, –4.2 to 1.0). In the multivariable analysis, digoxin was associated with a significantly higher risk of death among women (adjusted hazard ratio for the comparison with placebo, 1.23; 95 percent confidence interval, 1.02 to 1.47), but it had no significant effect among men (adjusted hazard ratio, 0.93; 95 percent confidence interval, 0.85 to 1.02; P=0.014 for the interaction). The effect of digoxin therapy differs between men and women. Digoxin therapy is associated with an increased risk of death from any cause among women, but not men, with heart failure and depressed left ventricular systolic function.Keywords
This publication has 40 references indexed in Scilit:
- Women, heart failure, and heart failure therapies.Circulation, 2002
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- Guidelines for the diagnosis and treatment of chronic heart failureEuropean Heart Journal, 2001
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approachesJournal of Cardiac Failure, 1999
- Heart Failure Survival Among Older Adults in the United StatesArchives of internal medicine (1960), 1999
- EditorialJournal of the American College of Cardiology, 1997
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart FailureJournal of the American College of Cardiology, 1996
- Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation, 1993
- Prevalence and mortality rate of congestive heart failure in the United StatesJournal of the American College of Cardiology, 1992